When unaffected control tissue (the caudate nucleus) is not available but specimens from patients such as those with AD and NPH are available, MAPT mRNA in combination with APP, TBXAS1, and ZCCHC8 can distinguish AD with higher accuracy than with a single biomarker. This evidence concerns the gene MAPT and Alzheimer disease.